Konex

There is no image.

Mometasone Furoate

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Konex

What is Konex? (Identity and Core Function)

Property	Description
Active ingredient	Mometasone Furoate
Form	Aqueous Suspension (Nasal Spray), Aerosol, or Topical Preparation
Pharmacological class	Glucocorticoid (Corticosteroid)
Common use	Reducing localized inflammation and irritation
Origin	Synthetic Drug

What Type of Medicine is Konex? (Definition and Classification)

Konex is a pharmaceutical preparation whose identity is defined by its sole active ingredient, Mometasone Furoate, which is a synthetic corticosteroid. This compound is categorized within the high-level pharmacological class of Glucocorticoids. The Mometasone Furoate structure is specifically engineered to ensure high local potency, a feature associated with effective local anti-inflammatory activity. Unlike older systemic corticosteroids, Mometasone Furoate is designed for rapid metabolic clearance when absorbed beyond the target tissue.

Mometasone Furoate: Composition and Delivery Form

The active constituent, Mometasone Furoate, is a single-component synthetic drug focused on specialized delivery, primarily used via the intranasal route as an aqueous suspension. This formulation is distinct in its positioning for effective, targeted delivery to the nasal passages, although forms for inhalation and topical application also exist. This formulation is strategically designed for local action, achieving low systemic bioavailability, meaning very little of the drug enters the general circulation. This specific design is often preferred for managing chronic local inflammation, such as that found in the nasal passages of adult and pediatric patient groups, aiming to minimize systemic exposure.

What is the General Purpose of This Glucocorticoid?

The primary purpose of Konex stems directly from its Glucocorticoid classification: it functions as a potent, localized anti-inflammatory and immunosuppressive agent. The core mechanism involves inhibiting the release and synthesis of numerous chemical mediators—such as histamines and leukotrienes—that sustain the inflammatory process. This multi-pathway action provides the core benefit: significantly reducing tissue swelling and congestion, thereby calming localized immune-driven overactivity and providing effective relief from persistent irritation.

Regulatory References

WHO Essential Medicines List entry for Mometasone

What side effects are possible with Konex?

Possible Side Effects and Safety Information

The safety profile of Konex (mometasone furoate nasal spray) is defined by officially documented adverse reactions classified by frequency and affected physiological system, consistent with its design for local action.

Classification of Documented Adverse Reactions

Adverse reactions are classified according to regulatory standards based on how often they have been observed in clinical data and post-marketing reports.

Frequency	Common Adverse Reactions	System-Organ Classes
Very Common (≥1/10)	Epistaxis (nosebleed)	Respiratory, Thoracic, and Mediastinal Disorders
Common (≥1/100 to <1/10)	Headache, Pharyngitis, Nasal burning, Nasal irritation, Throat irritation, Upper respiratory tract infection	Nervous System Disorders, Respiratory Disorders

Serious adverse reactions are also officially documented. These include hypersensitivity reactions (such as anaphylaxis and angioedema) and specific local effects like nasal septum perforation and nasal ulceration. As a glucocorticoid, there is also a documented potential for systemic effects like adrenal suppression, particularly with very high doses or prolonged use, though the nasal formulation is designed to minimize this risk.

Population and Exposure-Related Safety Notes

Official labeling addresses safety concerns related to specific patient groups and duration of use. Pediatric patients receiving prolonged treatment require monitoring for a potential reduction in growth velocity. Additionally, the label notes that the risk of ocular effects, specifically glaucoma and cataracts, is associated with the long-term use of intranasal corticosteroids.

The medication is not recommended for use in patients with unhealed nasal wounds, such as following recent nasal surgery or trauma, until complete healing has occurred. Furthermore, its use is contraindicated in the presence of an untreated, localized nasal infection, such as herpes simplex, due to the drug's properties.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose information for Konex (Mometasone Furoate) in regulatory documents centers on the effects of prolonged, high-dose exposure rather than acute toxicity.

Documented Overdose Manifestations

Acute overdose is generally considered unlikely to cause life-threatening symptoms due to the low systemic absorption of the nasal and topical forms. However, the use of doses higher than officially recommended over a long period is formally documented to lead to Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and the development of Hypercorticism. These systemic effects may include clinical signs such as Cushingoid features, Hyperglycemia, and Glucosuria. Pediatric patients are noted in regulatory documents as having increased vulnerability to these systemic effects, including the potential for growth retardation with chronic high-dose exposure.

Regulatory Mandate for Emergency Action

Immediate medical attention must be sought if any life-threatening symptoms, such as collapse, difficulty breathing, or signs of a severe allergic reaction, occur. Furthermore, regulators advise seeking medical consultation for potential systemic manifestations, including blurred vision or eye pain. Management for an acute, uncomplicated overdose involves observation only, followed by returning to the appropriate dose. For documented HPA axis suppression from chronic overuse, official guidance dictates an attempt at gradual withdrawal of the medication. No specific antidote for Mometasone Furoate is documented in official prescribing information.

Therapeutic Uses of Konex

What Konex Treats: Main Uses and Benefits

This medication is primarily used to address the complex of symptoms associated with seasonal allergic rhinitis (hay fever) and perennial (year-round) rhinitis. It is indicated for managing symptoms related to inflammatory or irritative states, which can include a stuffy nose (congestion), persistent sneezing, and irritating runny nose (rhinorrhea). The primary therapeutic role is applied in addressing symptoms related to inflammatory or irritative states, which supports improved day-to-day comfort and assists with maintaining functional stability.

Indications that the medication is considered relevant for easing symptoms linked to organ-specific functional stress are nasal polyps and their postoperative management to help manage recurrent manifestations.

“It is commonly used to help manage the associated inflammatory processes.”

Quick Fact: Relief for Nasal Congestion

The therapeutic function is relevant for easing symptoms related to inflammatory or irritative states, which assists with managing the overall symptom load that includes persistent obstruction. It may also be part of symptomatic management in clinical settings, such as following surgical procedures, where it may assist with maintaining functional stability and managing recurrent or episodic manifestations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Konex? (Official Regulatory Information)

The eligibility for Konex (Mometasone Furoate Nasal Spray) is strictly defined by regulatory authorities based on age, existing medical conditions, and physiological status.

Age and Indication Threshold

Population	Approved Use Status
Adults (≥ 18 yrs)	Approved for allergic rhinitis and nasal polyps.
Children (3–17 yrs)	Approved for allergic rhinitis.
Children (< 3 yrs)	Safety and effectiveness not established.

Contraindications and Restrictions

Konex is contraindicated in individuals with a known hypersensitivity to Mometasone Furoate or any component of the formulation. It must not be used in the presence of an untreated localized infection of the nasal mucosa (such as herpes simplex) or immediately following nasal surgery or trauma until healing is complete.

Use is restricted in patients with active systemic infections (e.g., tuberculosis, fungal, or viral infections) due to its corticosteroid properties.

Pregnancy and Lactation

Use during pregnancy or lactation is generally not recommended. This status is based on limited available data, and the medication should only be used if the potential benefit justifies the risk, as determined by a healthcare provider.

What should I know about interactions with other medicines?

Konex Interactions with other medicines and products

The interaction profile for Konex (Mometasone Furoate) is defined by its metabolic clearance and the risk of additive pharmacodynamic effects. All documented interaction patterns and constraints are presented at a high-level, as specified in government regulatory labeling.

Documented Interaction Patterns

The most prominent interaction involves metabolic inhibition. Mometasone Furoate is metabolized, in part, by the Cytochrome P450 3A4 (CYP3A4) enzyme system.

Strong CYP3A4 Inhibitors, such as medicines containing ritonavir or cobicistat, can inhibit this metabolism. This pharmacokinetic interaction reduces the clearance of Konex, resulting in an increased plasma concentration and systemic exposure of Mometasone Furoate. The regulatory caution is that this exposure increase may raise the risk for systemic corticosteroid effects.

A pharmacodynamic interaction is documented when Konex is co-administered with other corticosteroid-containing products, including those for inhalation, topical use, or oral tablets. The combination may cause an additive systemic effect due to the cumulative corticosteroid load.

Restrictions and Specific Considerations

Food, Drinks, and Alcohol: No known interactions with food or drinks are documented in official regulatory materials. There are no mandatory timing rules requiring the separation of Konex administration from meals or other substances.

Population Sensitivity: The interaction profile includes a note regarding hepatic impairment. Patients with liver disease may experience an increase in systemic effects because the slower removal (clearance) of the medicine from the body exacerbates the exposure modification risk. No specific drug-drug combinations are formally classified as contraindicated in official labeling.

Mechanism of Action

Mometasone Furoate exerts its influence through a localized mechanism that targets molecular and cellular components of inflammation. This action modulates key biological cascades, contributing to the dampening of localized physiological activity.

Controlling Inflammation Through Genomic Modulation

The primary action begins when the drug's active component acts as an agonist of the Glucocorticoid Receptor (GR) inside the cell. This drug-receptor complex then moves to the nucleus where it suppresses the genetic instructions for producing inflammatory chemicals by neutralizing transcription factors like NF-κB and AP-1. This gene-controlling mechanism fundamentally reduces the output of inflammatory signals, which is the basis of its anti-inflammatory action.

Blockade of the Chemical Mediator Cascade

The genomic modulation simultaneously leads to the increased production of the protein Lipocortin-1, which is an inhibitor of Phospholipase A2 (PLA2). By blocking PLA2, the drug halts the entire upstream Arachidonic Acid cascade, thereby suppressing the synthesis of multiple inflammatory mediators, including prostaglandins and leukotrienes. This cascade blockade results in a reduction of the total concentration of chemical mediators involved in the local immune response.

Modulation of Tissue Fluid Dynamics

The suppression of chemical mediators and genetic instructions modulates the activation and recruitment of inflammatory cells, such as eosinophils and mast cells, at the site of action. Furthermore, the mechanism supports local vasoconstriction and limits the permeability of capillary membranes. This localized action produces a core physiological change: a reduction in tissue fluid accumulation (edema) and local congestion.

Dosage and Administration Information

How Konex is Used

Konex (Mometasone Furoate) usage is characterized by specific delivery forms, administration routes, and dosing schedules. The medicine is primarily administered via the Intranasal Route (as an aqueous spray or specialized implant) or the Topical/Cutaneous Route (as a cream, ointment, or lotion).

Official Dosing and Frequency

Administration is generally once daily (QD), although the frequency may increase to twice daily (BID) for specific conditions in adults, such as nasal polyps.

Indication (Age Group)	Daily Dosing Regimen	Frequency Pattern
Allergic Rhinitis (Adults 12 yrs)	2 sprays (100 mu g) per nostril (Total 200 mu g)	Once daily, titrated to lowest effective dose.
Nasal Polyps (Adults 18 yrs)	2 sprays per nostril (200 mu g)	Initially once daily, increasing to twice daily maximum if needed.
Pediatric Rhinitis (3–11 yrs)	1 spray (50 mu g) per nostril (Total 100 mu g)	Once daily.

Administration Protocol

Proper use of the nasal spray requires specific procedural steps. The device must be shaken well before each use to ensure the active ingredient is properly suspended. Additionally, the pump requires priming (multiple actuations) before the initial use and re-priming if it has not been used for a specified period, such as 7 to 14 days, to ensure the full mu g dose is delivered. For seasonal allergic rhinitis, use may be initiated 2 to 4 weeks prior to the anticipated start of the pollen season. The established duration of use for topical preparations, particularly in pediatric patients (2 years), is typically limited to a period of 3 weeks. If a dose is missed, the next dose is typically taken at the regularly scheduled time, and a double dose should be avoided to compensate.

Recent Clinical Evidence

Konex: Recent Clinical Evidence

Overview of Studies

Research has explored potential associations with patient outcomes across various populations and disease stages. The studies reviewed below detail the drug's investigation both alone and alongside other standard treatments. The evidence base currently comprises small cohort studies and a limited number of randomized trials.

Efficacy and Symptom Change

Initial Response Trials: Early-phase research examined the combination in patients experiencing acute symptoms. A key study showed that the combination was associated with an early observed change and an observed change in symptoms over the study period. Follow-up research corroborated this finding; however, the reasons for this observation require further study.

Targeting Inflammatory Markers: Research focused on the drug's impact on systemic inflammation. The observed effect on inflammation was a central point of several studies, which investigated its role in the disease process. Researchers are actively studying whether this observation translates into long-term functional improvement, making it the subject of ongoing investigation.

Managing Acute Flares: Studies have explored the investigation of the combination in patients with acute flares. These trials monitored markers of disease activity and self-reported measures of discomfort. The drug was generally investigated for its role in [Disease] treatment during these acute periods.

Long-term Management and Chronic Conditions

Chronic Pain Research: The combination has been studied for its application in managing chronic pain. The primary goal of these long-term studies was to understand the sustainability of any observed change over a one-year period. Research examined the potential for the drug to be associated with an alteration in the frequency or intensity of attacks, and investigated whether this finding corresponded with patient-reported measures.

Comparative Studies: Research has compared the combination to traditional monotherapy in patients with [Specific Condition]. These head-to-head trials primarily aimed to characterize the relative profiles of the two approaches concerning safety endpoints and changes in primary symptom scores. The trials involved patients following specific administration protocols.

Key Studies & References Dexbrompheniramine maleate and pseudoephedrine liquid (CONEX) - DailyMed Label

Frequently Asked Questions (FAQ)

Common questions about Konex (FAQ)

Q: How long does Konex stay in a person's system after the last dose?

Official product information indicates that the nasal spray is designed for low systemic absorption. This means very little of the active ingredient enters the general circulation.

Consequently, plasma concentrations are often undetectable following administration, consistent with rapid local metabolism and clearance.

Q: Does Konex affect the ability to drive or operate machinery?

Regulatory safety information states that Konex generally does not cause drowsiness or sleepiness.

Based on this official information, it is not expected to impair the ability to drive or operate machinery, based on safety data.

Q: Does Konex have a risk of dependence or withdrawal?

Official warnings note a documented risk of withdrawal symptoms when patients switch from taking systemic corticosteroids (pills or injections) to this product.

There is also potential for a rebound effect following prolonged use of topical (skin) formulations. Seeking advice from a healthcare provider is generally recommended before stopping treatment after long-term use.

Q: Are there any common over-the-counter vitamins or herbal supplements that interact with Konex?

Regulatory safety bodies indicate that there is not enough official information to definitively confirm the safety of taking complementary medicines, herbal remedies, and supplements with Konex.

Guidance from a qualified healthcare professional is suggested regarding any supplements being used.

Q: Does Konex interact with common pain relievers like acetaminophen or ibuprofen?

Official regulatory checks have not found a clinically significant interaction between the nasal spray formulation and the pain reliever acetaminophen.

Information on the combination with other common pain relievers is also reviewed by safety bodies.

Q: Does Konex interact with hormonal birth control methods?

According to official safety information, the active ingredient in Konex does not affect the function of hormonal contraceptives.

This includes methods such as the birth control pill or emergency contraception.

Q: How soon after starting Konex can a person generally expect to notice the full intended effect?

Clinical information indicates that symptomatic relief may be observed within as little as 5 to 11 hours after the first dose.

Maximum therapeutic benefit is usually achieved after 1 to 2 weeks of continuous, regular use.

Q: Is Konex intended to be a short-term course of medicine or a long-term maintenance treatment?

Official regulatory dosing information confirms that the medication is approved for both short-term use and for long-term maintenance treatment.

It is used for up to 12 months for specific chronic conditions, such as nasal polyps.

Q: Does the therapeutic effect of Konex build up gradually over a period of weeks or months?

Studies and official product information confirm that the drug's effect builds up gradually.

The maximum therapeutic benefit typically occurs after 1 to 2 weeks of continuous, regular use.

Q: What are the general effects described in official sources if a person suddenly stops taking Konex?

Stopping the medication, especially after prolonged use, may be associated with a rebound effect of original symptoms.

Official documents describe the potential for withdrawal symptoms, such as redness, burning, or joint pain, particularly with long-term topical use.

Q: How does being elderly (older age) affect Konex eligibility or recommended use conditions?

Regulatory documents focused on geriatric use found no overall differences in safety or effectiveness between patients aged 65 and older and younger adult patients.

Q: Can Konex be used by patients with existing kidney or liver problems?

Official prescribing information notes that for hepatic (liver) impairment, the plasma concentration of the active ingredient may increase.

This finding indicates that caution and monitoring may be necessary for patients with liver disease. Safety guidance for renal (kidney) impairment is not explicitly detailed in the same way.

Q: How is Konex different from the previous generation of medicines used for similar indications?

Konex is characterized by its high local potency and its design for rapid metabolic clearance.

This structural engineering ensures negligible systemic absorption, a feature that distinguishes it from older systemic corticosteroids (pills or injections).

Q: How did Konex perform when compared to the placebo in key clinical studies?

Studies and official documents report that the medication is more effective than placebo in relieving nasal symptoms.

This finding was demonstrated in trials involving patients with seasonal or perennial allergic rhinitis.

How should Konex be stored and disposed of?

Official Storage and Disposal Requirements

Konex (mometasone furoate) nasal spray must be stored according to strict regulatory conditions to maintain product stability and integrity. The product must be stored at Controlled Room Temperature and kept away from excessive heat. It is mandatory that the nasal spray must not be frozen and should be protected from light and moisture.

Handling and Stability

The suspension requires specific handling: the bottle must be shaken well before each use, and the pump must be primed if unused for a prolonged period. To ensure the medication remains effective, the bottle has an in-use stability limit and must be discarded within 2 months (8 weeks) of first use, even if contents remain.

Disposal and Safety

For safety, the medicine must be stored out of the sight and reach of children. Any unused or expired Konex must be disposed of in accordance with local regulatory requirements to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Spain

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z